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ABSTRACT
Background: Recently, some common foods in daily life have been found to have anti-allergic effects. We
have reported that tomato extract (TE) could possibly inhibit histamine release and mouse ear-swelling re-
sponses. Moreover, it is reported that TE could relieve the symptoms for Japanese cedar pollinosis.
Methods: To evaluate the anti-allergic effect of TE, we performed a randomized, double-blind, placebo-
controlled study in 33 patients with perennial allergic rhinitis (PAR) using oral administration of TE (360 mg per
day) or placebo for 8 weeks.
Results: We found that the sneezing score significantly decreased in the TE group at the end of the trial com-
pared to the beginning (P < 0.05). There were decreasing tendencies of rhinorrhea and nasal obstruction in the
TE group. The patients’ quality of life was significantly improved in the TE group after 8 weeks of treatment (P <
0.05), but not in placebo group. A significant improvement in total symptom scores, combining sneezing, rhinor-
rhea and nasal obstruction, was observed after oral administration of TE for 8 weeks (P < 0.01). The safety of
TE treatment was confirmed by laboratory tests and inspection of general conditions.
Conclusions: TE can be expected to safely improve the nasal symptoms of PAR.
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INTRODUCTION
Allergic diseases, such as allergic rhinitis, bronchial
asthma and atopic dermatitis, have increased dramati-
cally in the past decades. PAR is one of the represen-
tative allergic diseases. Its prevalence reached 18.7%
in the Japanese population, which is higher than that
of cedar pollinosis (16.2%).1 The therapeutic strategy
is usually focused on removal and evasion of antigens
by environmental maintenance and pharmacother-
apy. Inhibitors of chemical mediators, anti-
histamines, and topical steroids are used widely, but
their potential side-effects are of concern with long-
term application.
Recently, some common foods in daily life have
been found to have anti-allergic effects. There is a
growing interest especially in regard to the anti-
allergic effects of plant polyphenols, some of which
are also contained in tomatos. We have recently re-
ported that tomato extract (TE), extracted from to-
mato skin with 60% aqueous ethyl alcohol, could in-
hibit histamine release from rat peritoneal mast cells
stimulated by a 4080 compound and mouse ear-
swelling responses.2 In addition, we have confirmed
the anti-allergic activity of naringenin chalcone (Fig.
1), the main active component of TE, in our previous
experimental study. Moreover, it is reported that TE
can relieve the symptoms of Japanese cedar pollino-
sis.3 These findings collectively indicate that TE may
have therapeutic efficacy in allergic rhinitis.
In this study, we confirmed the anti-allergic activity
of TE in a randomized, double-blind, placebo-
controlled clinical trial in patients with PAR.
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Fig. 1 Chemical Structure of Naringenin Chalcone, the 
Main Active Compound in Tomato Extract.
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OH Table 1 Characteristics of patients enroled in the study
PlaceboTomato extract
1617n
35.4 ± 3.1 34.7 ± 2.6 Age (mean)
Sex
 7 7male
 910female
Severity
 9 8Mild
 6 7Moderate
 1 2Severe
Symptom score
0.94 ± 0.171.18 ± 0.10Sneezing
1.25 ± 0.171.41 ± 0.19Rhinorhea
0.94 ± 0.191.29 ± 0.14Nasal obstruction
0.44 ± 0.130.82 ± 0.13＊QOL score
＊p＜0.05 compared between two groups
METHODS
SAMPLE PREPARATION OF TOMATO EXTRACT
(TE)
Tomato (Lycopersicon esculentum Miller) extracts
containing polyphenols were prepared from a mix-
ture of its seeds and skin with 60% (vv) ethyl alcohol
at 60℃ for 2 hours with subsequent lyophilization.
This extract contains 0.2% of naringenin chalcone.
SUBJECTS
Thirty-three adult PAR patients (14 men, 19 women,
range 18―56 years of age) were enrolled in the clini-
cal study. The inclusion criteria for PAR were that the
positive results be confirmed in at least two of the fol-
lowing three tests according to the Guidelines for the
Management of Allergic Rhinitis in Japan (2002)1: (a)
the allergen skin test or serum allergen-specific IgE
against house dust or mites; (b) the nasal provocation
test; and (c) eosinophil count in nasal discharge.
Each subject had a history of PAR for more than
three years. Prior to participation in the present
study, written informed consent was obtained from all
patients. In addition, this study followed the tenets of
the declaration of Helsinki.
The exclusion criteria included the following: (a) a
combination of other nasal diseases; (b) sensitization
to other allergens which may influence the study; (c)
complicated by systematic diseases; (d) attending an-
other clinical trial simultaneously; (e) pregnancy or
lactation; (f) poor condition when taking tomatos; and
(g) inappropriate cases for the trial defined by physi-
cians.
Detailed characteristics of recruited patients are
described in Table 1. Among a total of 33 patients
with PAR, 17 cases (51.5%) were diagnosed as mild,
13 cases (39.4%) were moderate, and 3 cases (9.1%)
were severe according to the scores of three main na-
sal symptoms (sneezing, rhinorrhoea and nasal ob-
struction), on the basis of the guidelines.
STUDY DESIGN
A randomized, double-blind, placebo-controlled trial
was performed at three institutions (Japanese Red
Cross Society Wakayama Medical Centre, Dake ENT
Clinic and Okuno ENT Clinic) in Wakayama and
Osaka, Japan between October 2004 and January
2005, in order to avoid the influence of the Japanese
cedar pollen season. This study was conducted at the
TTC Co., Ltd. and was approved by the ethics com-
mittee of the Kaiyuu Clinic.
METHODS
Subjects were randomly divided into two groups. One
group of patients received an oral administration of
tablets containing 360 mg of TE per day (TE group;
n = 17) and another group received placebo (placebo
group; n = 16). The placebo tablet contained dextrin
in place of TE, with the same color and taste as the
TE tablet. Each subject received two tablets t.i.d. per
day for a course of 8 weeks. The clinical characteris-
tics of patients in both groups are shown in Table 1.
There were no significant differences among the pa-
tient characteristics.
The severity of nasal symptoms (sneezing, rhinor-
rhea and nasal obstruction) was scored using a pa-
tient diary, which was in accordance with the guide-
lines, written by patients themselves each day during
the study. A questionnaire on quality of life (QOL) in-
vestigated issues in daily life, such as ‘interference
with work, study or housework’, ‘sleep disorder’ and
‘limitation on going out’. Responses were evaluated
using five-grades based on the guidelines.
During the study period, each patient visited a doc-
tor three times: at the beginning of the trial, week 4
during the trial, and at the end of the trial (week 8).
The patient’s diary was checked to score the degree
of nasal symptoms, and the nasal signs (mucosal
swelling, mucosal color, discharge volume and char-
acter) were evaluated on the basis of the guidelines.
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Fig. 2 Mean change rates from baseline of scores, evaluated using patient diaries in tomato extract (TE) (closed circle) 
and placebo (open circle) groups, (a) sneezing, (b) rhinorhea, (c) nasal obstruction and (d) quality of life. The starting 
day of administration (baseline) is indicated on the graphs as 0 week. TE or placebo were administrated from 0 to 8 
weeks, after the administration folow-up period was set up for one week (8 to 9 weeks). Each value is the mean ＋ /－ 
SE. ＋P＜0.10, ＊P＜0.05 compared with baseline in each group.
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Fig. 3 Mean score change of total nasal symptom score, 
evaluated by a physician, from baseline in tomato extract 
(TE) (closed circle) and placebo (open circle) groups. The 
starting day of administration (baseline), 4 weeks after the 
start of administration and 8 weeks after administration (end-
point) are indicated on the graph as 0, 4 and 8 weeks, 
respectively. Each value is the mean ＋ /－ SE. ＊＊P ＜0.01 
compared with baseline in each group.
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Fig. 4 Mean change rate of ECP in serum from baseline 
in tomato extract (TE) (closed circle) and placebo (open cir-
cle) groups. The starting day of administration (baseline), 4 
weeks after start of administration and 8 weeks after admini-
stration (end-point), are indicated on the graph as 0, 4 and 8 
weeks, respectively. Each value is the mean ＋ /－ SE.
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The medication was recorded by drug character and
using points according to the guideline as follows:
second-generation antihistamines, mast cell stabiliz-
ers, vasoconstrictor or anti-cholinergic nasal drops,
and mast cell stabilizer eye drops, 1 point, respec-
tively; topical ocular and nasal steroids, 2 points, re-
spectively. Any concurrent use of drugs that could in-
fluence the evaluation of efficacy was prohibited.
Peripheral blood and urine route examinations
were performed three times when the patient visited
the physician. Serum allergen-specific IgE (house
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Table 2 Serum IgE titer
8 weeks4 weeks0 weeks
902.5 ± 551.9876.7 ± 533.51041.4 ± 691.2 Tomato extractTotal IgE
(IU/ml) 305.5 ± 156.8382.5 ± 224.1378.4 ± 218.0Placebo
3.6 ± 0.43.5 ± 0.43.6 ± 0.4Tomato extractMites
2.8 ± 0.32.9 ± 0.32.8 ± 0.3PlaceboClass
3.6 ± 0.43.5 ± 0.43.5 ± 0.3Tomato extractHouse dust
2.7 ± 0.32.7 ± 0.32.6 ± 0.3PlaceboClass
0.6 ± 0.20.6 ± 0.20.6 ± 0.3Tomato extractMugwort
0.7 ± 0.30.8 ± 0.30.8 ± 0.3PlaceboClass
2.4 ± 0.42.2 ± 0.32.2 ± 0.3Tomato extractCedar polen
1.8 ± 0.41.8 ± 0.41.8 ± 0.4PlaceboClass
Table 3 Eosinophil count in nasal discharge
－±1＋2＋3＋
20 8700 weeks
Tomato extract 2011404 weeks
20 7718 weeks
20 8600 weeks
Placebo 20 6804 weeks
1013208 weeks
dust, Dermatophagoides pteronyssinus, Japanese cedar
pollen and Artemisia pollen) and eosinophil cationic
protein (ECP), and eosinophil count in nasal dis-
charge were also measured.
STATISTICAL ANALYSIS
Data were expressed as the mean ± SE. Clinical study
data was analyzed as follows; the ANOVA test was
used to evaluate differences between the group’s
mean scores, and a non-parametric combination test
was used to evaluate differences between groups. Sta-
tistically significant differences were considered
when P < 0.05. The statistical analysis was performed
using SPSS software.
RESULTS
NASAL SYMPTOMS AND SIGNS
The rate of change in patients’ score of nasal symp-
toms and QOL during the study are shown in Figure
2. We found that the sneezing score of the TE group
significantly decreased at the end of the trial (week 8)
compared to the beginning of the trial (P < 0.05, Fig.
2a). However, the score returned to the baseline
within one week after the trial (week 9, Fig. 2a). In-
terestingly, the patients’ QOL was significantly im-
proved in the TE group at week 5 and 8 (P < 0.05, Fig.
2d). Moreover there were decreasing tendencies of
rhinorrhea and nasal obstruction in the TE group
(Figs. 2b and c). In the placebo group, no significant
change of nasal symptoms was found during the trial
(Fig. 2).
A significant improvement of total nasal symptom
scores, combined sneezing, rhinorrhea and nasal ob-
struction, was observed after oral administration of
TE for 8 weeks (P < 0.01, Fig. 3).
Overall, the scores of nasal signs based on the phy-
sician examination showed no significant changes
during the trial either in the TE group or the placebo
group. After 8 weeks of treatment, the amount of na-
sal discharge showed a marginal decrease in the pla-
cebo group compared to the TE group.
ALLERGIC TESTS
As shown in Figure 4, there was no significant differ-
ence in the change of ECP concentration in the se-
rum between the TE and placebo groups. However, a
decreasing tendency of ECP concentration was ob-
served at the end of the trial in the TE group com-
pared with the beginning (P = 0.147, Fig. 4). Serum
allergen-specific IgE levels and eosinophil count in
nasal discharge showed no significant changes dur-
ing the study period (Tables 2, 3).
SAFETY
No adverse effects were observed throughout the
study. Cold and diarrhea were reported by some pa-
tients but the degree was slight and disappeared dur-
ing the study, which may have had no relationship
with the trial. There was no significant change in the
results of the urinalysis, blood or biochemistry in-
Tomato Extract Improves Allergic Rhinitis
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spection during the study period in the two groups.
DISCUSSION
In Japan, cedar pollinosis remains a public health
problem. However, the prevalence of PAR, mainly
caused by house dust and mites, is higher than that
of Japanese cedar pollinosis.1 PAR attacks in all sea-
sons and also dominates in younger children, which
makes it harder to be cured. Now, many kinds of
medicine have been developed and applied clinically.
Patients typically need to use these drugs for an en-
tire year with consideration of their side-effects. Addi-
tionally, there are only a few kinds of medicine that
are appropriate for younger children.
With this background, it is interesting to find food
with anti-allergic effects, which could be expected to
reduce the dependence on drugs to some extent. Re-
cently, many experimental and clinical studies have
been carried out for this purpose in Japan, but reports
on anti-allergic foods were mainly against cedar polli-
nosis, such as lactic acid bacterium,4-9 and plant ex-
tract such as sweet tea,10,11 perilla leaf and seed12,13
and persimmon leaf,14 suggesting an anti-allergic ac-
tivity of plants with polyphenols.
We have searched for anti-allergic components in
various kinds of fruits and vegetables, and found that
TE has activity in inhibiting histamine release from
mast cells stimulated by a 4080 compound.2 The
main active component of TE is naringenin chalcone,
which is one kind of polyphenol and exists in the skin
of red tomatos, but not in pink tomatos.15
TE could be used as a new preventive and thera-
peutic modality if the materials from such foods can
be shown to prevent allergic diseases and relieve al-
lergic symptoms. Ryu et al. have reported that 360
mg of TE per day significantly improved 8 of 11 sub-
jective allergic symptoms, and 1 of 5 contents of QOL
in 24 volunteer patients with Japanese cedar pollino-
sis during the peak of pollen scattering.3 This fact in-
dicates that TE may improve allergic symptoms of
pollinosis. This suggested that TE might improve al-
lergic symptoms not only in cedar pollinosis but also
in PAR.
In the present study, we evaluated the clinical ef-
fects and safety of TE for PAR treatment. Patients in
the TE group did not show serious adverse events
throughout the study period, suggesting that TE is a
safe food. Considering TE is at first a type of food, we
performed this study on mild-to-moderate, but not se-
vere patients. In addition, this study is designed as a
randomized, double-blind, placebo-controlled trial,
and a relatively long test period of 8 weeks was set.
Although there was no significant change in nasal
signs by physician examination, patient QOL and na-
sal symptoms, especially sneezing, improved with the
intake of TE. This result suggested that TE is useful
in controlling PAR; however, it likely does not act so
quickly in the case of cedar pollinosis.3 It is known
that type I allergy has two phases of allergic re-
sponse, i.e. an early phase and late phase. The early
phase response is caused by chemical mediators,
such as histamine, thromboxanes and leukotrienes
released from mast cells after stimulation of antigen,
and is the main mechanism in the onset of cedar polli-
nosis. The late phase response is caused by chemical
mediators, such as LTs and ECP, and causes PAR
generally.16 The anti-allergic function of TE is attrib-
uted more to inhibition of histamine release from
mast cells than an anti-histamine effect. Therefore,
TE acts more quickly in the case of cedar pollinosis
than in PAR.
This clinical study showed a decreasing tendency
of ECP concentration. ECP is one of the chemical me-
diators released from eosinophils and its quantity is
controlled by the activity and quantity of eosino-
phils.17,18 TE inhibited release of some chemical me-
diators in the animal inflammation model.2 TE might
inhibit release of chemical mediators, such as ECP,
by decreasing eosinophils and, as a result, might in-
hibit allergic reactions. However, the mechanism re-
mains unknown. The detailed pharmacological
mechanisms and clinical outcomes of TE need to be
investigated further.
In conclusion, the oral administration of TE can be
expected to safely improve the nasal symptoms of
PAR. The TE dosage and administrative period were
fixed in the present trial. Further studies are needed
to discuss the most appropriate dosage and intake pe-
riod in a large sample of patients with allergic rhinitis.
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